Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Rhea-AI Summary

Crescent Biopharma has announced its upcoming presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT. The company will showcase its lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody being developed for solid tumor treatment.

The presentation will be available via live webcast, with a recording accessible for 90 days afterward. This announcement follows Crescent's recent acquisition agreement with GlycoMimetics (NASDAQ: GLYC) in October 2024. Post-merger, the combined entity will operate as Crescent, focusing on advancing precision-engineered biologics for solid tumor treatments.

News Market Reaction

-5.29%

1 alert

-5.29% News Effect

On the day this news was published, GLYC declined 5.29%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors

WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

A live webcast of the presentation will be available at https://wsw.com/webcast/jeff315/cresc/1987776. An archived recording will be available for 90 days following the event.

In late October, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ: GLYC). Following closing, the combined company will operate under the name Crescent and advance its portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors.

About Crescent Biopharma
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best-in-class therapeutics. For more information, visit www.crescentbiopharma.com. 

Media Contact:
Deerfield Group
Lia Dangelico
540-303-0180
lia.dangelico@deerfieldgroup.com

Investor Contact:
Argot Partners
Dawn Schottlandt
212-600-1902
dawn@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/crescent-biopharma-to-present-at-jefferies-london-healthcare-conference-2024-302301827.html

SOURCE Crescent Biopharma

FAQ

When is Crescent Biopharma presenting at the Jefferies London Healthcare Conference 2024?

Crescent Biopharma is presenting at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

What is the acquisition status between Crescent Biopharma and GlycoMimetics (GLYC)?

In late October 2024, Crescent Biopharma entered into an acquisition agreement with GlycoMimetics (NASDAQ: GLYC), with the combined company to operate under the Crescent name.

What is Crescent Biopharma's lead program for solid tumor treatment?

Crescent Biopharma's lead program is CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors.

How long will the Jefferies Conference presentation webcast be available for viewing?

An archived recording of the presentation will be available for 90 days following the event.